Loading company
Pulmatrix, Inc.
PULM · Nasdaq · ·
Next earnings: October 15, 2026
$1.61+0.6%Sep 29 close
- 1M
- +6.6%
- 6M
- +30.9%
- 1Y
- -66.9%
- 5Y
- -90.2%
PULM · Nasdaq · ·
Next earnings: October 15, 2026
$1.61+0.6%Sep 29 close
Pulmatrix, Inc. is scheduled to report next on October 15, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $3K | $2.2M | -99.86% |
| Profit | -$1M | -$1.5M | +33.12% |
| Profit per share | -$0.29 | -$0.42 | +30.95% |
| Free Cash Flow | -$1.3M | -$2.3M | +45.55% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Inc. Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company’s proprietary product pipeline includes treatments for central nervous system (“CNS”) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and allergic bronchopulmonary aspergillosis (“ABPA”). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. For more on the Company’s inhaled product candidates please visit: https://www.pulmatrix.com/pipeline.html .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Pulmatrix, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Pulmatrix, Inc. has no earnings call transcript available.